GSK Partnership With Immatics Seeks TCR Therapeutics For Solid Tumors
Deal Snapshot: GSK obtains rights to two of Immatics’ TCR targets, following on the German firm’s similar deals in recent years with Celgene, Genmab and Amgen.
You may also be interested in...
Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Immatics' T-Cell Redirecting Immunotherapies Impress In Solid Tumors
The promise of Immatics’ T-cell redirecting cancer immunotherapy technology for solid tumors has been spotlighted in early clinical studies in heavily pre-treated and refractory cancer patients.
Immatics To Go Public Through Merger With ‘Blank Check’ Company Arya
German TCR developer in partnerships with GSK and BMS will go public and receive $252m at closing in a reverse merger-type transaction with Arya.